Merck & Co.'s heavy reliance on its cancer drug Keytruda, which accounts for nearly half of the company's revenue, is raising investor concerns as the drug's patent expiration approaches in 2028 ...
The lender raised its dividend by 5% on year, after exceeding its medium-term growth target a year ahead of schedule.
(RTTNews) - Biopharmaceutical company Merck & Co., Inc. (MRK) reported Tuesday a net profit for the fourth quarter compared to a loss last year, reflecting improved gross margins, sharply lower R ...
Pyxis Oncology announces Phase 1/2 trials for PYX-201, combining it with KEYTRUDA® to treat advanced solid tumors. Pyxis Oncology, Inc. has announced the initiation of two significant clinical ...
Sales of top-selling cancer treatment Keytruda climbed 19% to $7.84 billion. Analysts expected earnings of $1.61 per share on $15.48 billion in revenue. Shares of Merck & Co. Inc. tumbled 10% ...
Cohort B is evaluating efti in combination with MSD’s anti-PD-1 therapy KEYTRUDA® (pembrolizumab) as first-line treatment of recurrent or metastatic head and neck squamous cell carcinoma patients (1L ...
Results have been announced from a Phase III trial of Merck & Co’s (NYSE: MRK) anti-PD-1 therapy Keytruda (pembrolizumab) plus Lenvima (lenvatinib), Eisai’s (TYO: 4523) orally available multiple ...
Summary: Entrepreneurs often grapple with the decision of whether to structure their business as a Company or a Limited Liability Partnership (LLP). Both offer the advantage of limited liability and ...
The combination of Merck’s Keytruda and Eisai’s Lenvima failed to prolong patients’ lives versus the comparator in another cancer study, but the companies ...
Merck (NYSE:MRK) and Esai (OTCPK:ESALF) (OTCPK:ESAIY) announced Friday a mixed outcome in their Phase 3 LEAP-015 trial, which was designed to evaluate MRK’s anti-PD-1 therapy Keytruda and the Ja ...
Merck & Co. and Eisai have to deal with the reality that yet another phase 3 trial of their combination of Keytruda and Lenvima didn’t exactly go their way. The Keytruda-Lenvima regimen ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback